These authors contributed equally.
Development of a Peptide that Selectively Activates Protein Phosphatase-1 in Living Cells†
Article first published online: 7 SEP 2012
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 51, Issue 40, pages 10054–10059, October 1, 2012
How to Cite
Chatterjee, J., Beullens, M., Sukackaite, R., Qian, J., Lesage, B., Hart, D. J., Bollen, M. and Köhn, M. (2012), Development of a Peptide that Selectively Activates Protein Phosphatase-1 in Living Cells . Angew. Chem. Int. Ed., 51: 10054–10059. doi: 10.1002/anie.201204308
J.C. thanks the Alexander von Humboldt Foundation and EMBO for postdoctoral fellowships. R.S. was funded by the EMBL-EIPOD program. M.K. acknowledges support from the German Science Foundation within the Emmy-Noether program. M.Bo. and M.Be. are supported by Flemish Concerted Research Action (GOA10/16), the National Science Foundation-Flanders (grant G.0478.08), the Prime Minister’s office (IAP-P6/28P, and the Cell Imaging Core of KU Leuven. A. Hoogmartens, T. Jaspers, N. Sente, G. Van der Hoeven, and A. McCarthy provided technical assistance. X-ray data was collected at SOLEIL synchrotron.
- Issue published online: 26 SEP 2012
- Article first published online: 7 SEP 2012
- Manuscript Received: 3 JUN 2012
- Funded Access
- Flemish Concerted Research Action. Grant Number: GOA10/16
- National Science Foundation-Flanders. Grant Number: G.0478.08
- Prime Minister’s office. Grant Number: IAP-P6/28P
- cell-penetrating peptides;
- drug design;
- enzyme activation;
- protein phosphatase-1;
- protein–protein interactions
Ser/Thr phosphorylation in proteins is fundamental to signal transduction processes in cells. Malfunction of these processes contributes to the development and progress of diseases. The phosphorylation of proteins on Ser and Thr residues is mediated by protein Ser/Thr kinases, whereas protein Ser/Thr phosphatases (PSTPs) hydrolyze protein-bound phosphomonoesters. Inhibitors of Ser/Thr kinases are widely used for functional studies and as therapeutic agents, but there are virtually no tools to target specifically the counteracting PSTPs in living cells.1 The major obstacle for the design of selective inhibitors of PSTPs lies in the similarity of the catalytic pocket, which so far has not allowed the development of selective, high-affinity active-site binders. Therefore, widely used potent inhibitors of PSTPs are not very useful for functional studies.2 Alternatively, enzyme activators have recently gained much attention.3 Although a possible activator of the PSTP protein phosphatase-1 (PP1) was reported in vitro,4 no studies for potency and selectivity in living cells have been presented to date. Thus, there is an urgent need to develop potent and selective molecules to target specific PSTPs in living cells.1, 2
PP1 is a ubiquitous enzyme that is predicted to catalyze the majority of Ser/Thr dephosphorylation in eukaryotic cells.5, 6 PP1 has a broad specificity but is restrained in vivo by numerous PP1-interacting proteins (PIPs) (roughly 200 in vertebrates) that form holoenzymes with the PP1 catalytic subunit and function, for example, as activity regulators or substrate-targeting proteins.6, 7 An attractive approach for the development of PP1-selective effectors is targeting specific interfaces between PP1 and PIPs and disrupting their interaction. One of these interfaces, which occurs in about 90 % of all validated PIPs, is referred to as the RVxF-type PP1-binding motif (single-letter amino acid code, x=any amino acid), which binds to a site on PP1 that is remote from the active site.8 Synthetic peptides that contain variants of the RVxF motif, but not the corresponding RAxA peptides, were reported to disrupt a subset of PIP–PP1 complexes in vitro.4, 7, 9 In general, disruption of protein–protein interactions by peptides is an appealing strategy to interrogate signaling pathways owing to their high affinity and specificity.10 Nevertheless, it needs to be considered that the application of peptides in living cells is often hampered by insufficient cell permeability and proteolytic instability.10
In our work we sought to develop a proteolytically stable, cell-permeable peptide that specifically disrupts PP1–PIP interactions and modulates PP1 signaling in living cells. As a lead PP1-disrupting peptide (PDP) we synthesized PDP0 (Table 1), comprising the RVxF motif (underlined) and flanking sequences of the nuclear inhibitor of PP1 (NIPP1).9 The peptide was tested in a competition assay, in which PDP0-mediated release of PP1 from its PIP Inhibitor 2 (I2) was measured. I2 binds to PP1 through an RVxF motif and inhibits PP1. The release results in the deinhibition of PP1, which is measured using a phosphatase activity assay. PDP0 alleviated the inhibition of PP1 by I2 with an EC50 of 87±10 nM (Table 1 and Figure S1 in the Supporting Information). An alanine scan of PDP0 revealed the importance of the basic N-terminal stretch and the two C-terminal isoleucines for the potent deinhibition of PP1 (Figure 1 and Figure S2). These results were confirmed by C- and N-terminal truncation scans. When multiple amino acids were replaced with alanine at the two RVxF-flanking serine positions and the C-terminal acidic EDDE sequence, the disruption efficacy was further increased (Figure S3). Collectively, these data enabled us to design the optimized peptide PDP1 (Table 1 and Figures S1 and S3).
As the RVxF motif of PIPs binds in an extended conformation to PP1,8 we sought to develop D-Pro-L-Pro-templated linear peptides (Figure S4 in the Supporting Information) and D-Pro-L-Dap (L-Dap=L-2,3-diaminopropionic acid) templated disulfide-bridged cyclic peptides to display the RVTF motif in an extended conformation (Scheme S1 and Figure S5).11 However, constraining the peptide by cyclization resulted in the loss of deinhibition potency, which is consistent with the required conformational flexibility of the RVxF motif and its flanking sequences for binding to PP1.6 Taken together, alanine-, truncation-, multiple-alanine-, and D-Pro-L-Pro/Dap-scans revealed that the basic amino acid stretch (-KRKRK-) N-terminal to the RVTF motif and two hydrophobic residues (-II-) C-terminal to the RVTF motif in PDP0 are essential for binding to PP1. On the contrary, the acidic stretch (-EDDE-) and the two RVTF-flanking serines destabilize the binding of PDP0 to PP1.
Next, we assessed the cell permeability of the peptides using confocal microscopy by incubating live cells with 5-carboxyfluorescein (FAM)-labeled peptides. Confocal microscopy was chosen because it can distinguish intracellular peptides from peptides adhering to the extracellular cell surface. FAM-PDP1 did not penetrate cells efficiently (Figure 2 a), and showed extra- and intracellular aggregation in different cell types at higher concentrations (Figure S6 in the Supporting Information). We then applied an iterative design strategy involving the sequential addition of arginine/lysine residues to the N-terminus, thereby enhancing its cell penetration without significantly compromising its efficacy as a PP1–PIP-disrupting peptide. This led to the design of PDP2, which also disrupted the PP1:I2 complex but was slightly less efficient than the nonpermeable peptide PDP1 (Table 1). The corresponding RATA mutant of PDP2 (PDP2m), showed no effect in the deinhibition assays (Table 1), confirming the importance of valine and phenylalanine in mediating the high-affinity binding of PDP2 to PP1.
FAM-PDP2 was efficiently taken up into different cell lines at different concentrations, showing a diffuse cytoplasmic and nucleoplasmic distribution, and also to a minor extent potential vesicular localization or aggregation (Figure 2 b, Figure S6 in the Supporting Information). The differences in the cell-penetration efficiency of PDP1 and PDP2 can be ruled to be independent of the FAM label, as both peptides carry it. The uptake of FAM-PDP2 was lower at 4 °C than at 37 °C (Figure S7), suggesting both energy-dependent and -independent modes of uptake.12 FAM-PDP2m was taken up at least as well as FAM-PDP2 (Figure 2 b,c).
Once cell penetration was established, we addressed the selectivity of PDP2 toward binding the closely related phosphatases PP1 and PP2A. For this we precipitated biotinylated PDP2 and PDP2m from HEK293 (human embryonic kidney cells) (Figure 3 a) and U2OS cell lysates (Figure S8 in the Supporting Information) with streptavidin-coated Sepharose beads, which resulted in a dose-dependent co-sedimentation of PP1. PDP2 did not co-precipitate the structurally closest related PP2A (Figure 3 b), and did not show any specificity towards the three PP1 isoforms (α, β, and γ) (Figure S9). PDP2m co-precipitated neither PP1 nor PP2A (Figure 3 a,b). Furthermore, the efficacy of PDP2 in disrupting PP1 holoenzyme complexes was analyzed in vitro with freshly immunoprecipitated PP1 complexes using PIP-directed antibodies. The complexes were subjected to PDP2 and PDP2m, and subsequently assayed using 32P-labeled phosphorylase a as substrate, as detailed above. The resulting PP1 activity correlates with the level of released active PP1. The results demonstrate that PDP2, but not PDP2m, disrupted all the tested PP1 holoenzymes in vitro, further corroborating the potential of PDP2 as a cell-permeable disruptor of PP1 holoenzymes.
To understand in detail how PDP2 interacts with PP1, we solved the crystal structure of the PP1:PDP2 complex (Figure 4) at a resoluion of 3.1 Å. The structure shows that PDP2 binds in the same groove of PP1 (Figure 4 a) as other structurally characterized PIPs containing the RVxF motif.8, 13 Thirteen residues at the C-terminus of PDP2 (1-RRKRPKRKRKNARVTFAEAAEII-23) are observed in an extended conformation, with Arg13, Val14, Thr15, Ala17, Glu21, and Ile23 hydrogen bonding with backbone atoms of PP1. As in previous structures,8, 14 Val14 and Phe16 are buried in the binding groove and Arg13 interacts with PP1 Asp242 (Figure 4 b). The C-terminal isoleucine makes van der Waals contacts with PP1 Leu296, suggesting why alanine mutation of this residue resulted in a decreased potency. Hydrophobic contacts with PP1 Leu296 are also observed in the PP1:spinophilin complex.14 Mutation of the basic N-terminal residues of PDP2 led to a decreased potency, but these residues are not observed in the crystal structure. However, the position of the visible N-terminal residues of PDP2 suggests that these basic residues are located adjacent to a negatively charged region on the surface of PP1 (Figure 4 a). Thus, electrostatic interactions between this acidic region of PP1 and the basic N-terminus of PDP2 may additionally stabilize the complex.
To validate the physical association of PDP2 with PP1 in cell lysates, we designed photo-cross-linkable analogues by substituting Phe17 and Ala18 of PDP2 with L-4-benzoylphenylalanine (Bpa).16 The analogues were biotinylated to enable pull-down of the cross-linked complex out of the cell lysates. Bpa substitution at Phe17 failed to yield any cross-linked complex (Figure S11 in the Supporting Information). The peptide resulting from Bpa replacement of Ala18, PDP3 (Table 1), covalently cross-linked to PP1 upon irradiation with ultraviolet light (365 nm) in a dose-dependent manner (Figure 4 c), proving the direct physical interaction of PP1 with PDP3 in cell lysates. The efficient cross-linking of PDP3 to PP1 can be explained from the PP1:PDP2 crystal structure, where Met290 of PP1 is in close proximity to Ala18 which, when replaced by Bpa, presumably results in the formation of a covalent bond between Bpa and the Met290 side chain. As PDP3 covalently captured PP1 from cell lysates, we determined if it could also be employed in intact cells. Different cells took up FAM-PDP3 and FAM-PDP3m equally well (Figure S12), and FAM-PDP3 showed penetration properties similar to those of FAM-PDP2 (Figure S13). Like PDP2, biotinylated PDP3 did not co-precipitate PP2A (Figure S14).
Next, we explored the effects of PDPs on PP1 in intact cells. To this end, we first tested whether treating cells with PDPs would have an effect on the mitotic phosphorylation of histone H3 on threonine 3 (T3), a well-established PP1 substrate17 (Figure 5 a). Surprisingly, addition of PDP2 did not show any effect, even when a fivefold excess of PDP2 was employed relative to PDP3 (Figure S15 in the Supporting Information). On the contrary, PDP3 treatment promoted histone H3T3 dephosphorylation even though PDP3 has lower in vitro potency than PDP2, and a clear dose–response relationship was observed (Figure 5 b). We also tested whether biotinylation would have an effect. For acetylated and biotinylated peptides, similar behavior was observed (Figure 5 a). Since PDP2 and PDP3 penetrated cells to a similar extent, the better efficiency of PDP3 cannot be attributed to its better cell-penetration properties. Therefore, the higher efficiency of PDP3 could be explained by either a higher intracellular stability or its intrinsic cross-linking properties owing to the presence of Bpa, or a combination of both. However, the intrinsic cross-linking property of PDP3 can be ruled out based on our observation that incubation of PDP3 with cell lysates did not yield any cross-linked PP1 in the absence of UV irradiation (Figure 4 c).
To examine the hypothesis of increased stability, we compared the in-cell stability of FAM-PDP2 and FAM-PDP3. Intact U2OS cells (in mitotic arrest, to apply the same conditions as before) were incubated with various concentrations of FAM-PDP2 and FAM-PDP3 for 3 h and lysed to determine the remaining amount of the intact peptides by fluorescence in-gel scan (see the Supporting Information). The results clearly demonstrated that FAM-PDP3 was significantly more stable than FAM-PDP2 inside cells (Figure 6). This corroborated our hypothesis that the substitution of the canonical amino acid (Ala) in PDP2 with an unnatural amino acid (Bpa) greatly enhanced the cellular stability of PDP3. Since PDP3 is more stable than PDP2 inside cells, whereas PDP2 is more potent in vitro, and since their cell-penetration properties are similar, this finding also proves that PDP3 exerts its effect after penetrating the cells and not by adhering to the cell surface. Furthermore, our results demonstrate the difficulty in transferring probes, in particular peptidic ones, from an in vitro to an in-cell setting, as unexpected effects can occur.
Based on this finding, we used PDP3 for further experiments in living cells. As there were no differences in potency observed between biotinylated and acetylated forms (Figure 5 a), the biotinylated peptide was selected, enabling detection of the peptide in cells by immunofluorescence to further confirm and ensure PDP3s cell penetration ability (Figure S16 in the Supporting Information). First, we investigated disruption of PP1 holoenzymes by PDP3 in living cells. Following incubation of U2OS cells for 3 h with 10 μM PDP3, cell lysis, and analysis (see the Supporting Information), three of the five endogenous PIPs examined showed a reduced association with PP1 (Figure 7 a). These results demonstrate the efficacy of PDP3 in disrupting PP1 holoenzymes inside cells.
Next, we examined the effects of PDP3 on the mitotic phosphorylation of histone H3 on additional sites that are known to be dephosphorylated by PP1.17 PDP3 decreased the phosphorylation of histone H3 on Thr3 and Ser28, but did not significantly affect the phosphorylation of Ser10 and Thr11 (Figure 7 b). This is in accord with published data showing that the dephosphorylation of H3T3 and H3S28 in vitro proceeds with a lower concentration of PP1 than that required for the dephosphorylation of H3S10 and H3T11.17 PDP3m did not affect histone H3 phosphorylation (Figure 7 b), suggesting that PDP3 accelerates the dephosphorylation of selected residues on histone H3 in living cells by binding to PP1.
Despite having a cell-penetrating stretch, neither PDP3 nor PDP3m showed any cytotoxicity under the experimental conditions. However, when applying prolonged incubation times we observed cytotoxic effects of PDP3 but not PDP3m, showing that these effects can be attributed to increased PP1 activity inside cells and, notably, are not due to nonspecific toxicity of the polybasic stretch (Figure S17 in the Supporting Information).
During mitosis, H3T3ph is dephosphorylated by a complex of PP1 and the histone H3 PP1-targeting subunit Repo-Man.17 Since PDP3 also disrupted the PP1:Repo-Man complex (Figure 7 a), our data suggest that histone H3 can be dephosphorylated by nontargeted, PDP3-associated PP1. This suggestion was corroborated by examining the effects of PDP3 on mitotic H3T3ph after the siRNA-mediated knockdown of Repo-Man (Figure 7 c). A deficiency of Repo-Man resulted in a hyperphosphorylation of H3T3, but this was reversed by preincubation with PDP3, without any effect on the total level of PP1. PDP3 also induced the dephosphorylation of PP1 at Thr320 (Figure 7 c). This site is reported to be auto-dephosphorylated by PP1, resulting in partial activation of PP1 in a cell-cycle-dependent manner.18 Thus, in addition to disrupting PP1 inhibitory holoenzymes, Thr320 dephosphorylation can be another mechanism by which PDP3 activates PP1.
We next studied the downstream effects of enhanced histone H3 dephosphorylation by PDP3 during mitosis. H3T3ph serves as a docking site for Survivin, a regulatory subunit of Aurora B kinase, and mediates the targeting of this essential mitotic kinase to the centromeres during prometaphase.19 Consistent with this mitotic function of H3T3 phosphorylation, we found using immunofluorescence that PDP3, but not PDP3m, caused the centromeric loss of both H3T3ph and Aurora B in mitotically arrested U2OS cells (Figure 7 d–f). Similar effects have also been described after the knockdown of the H3T3 kinase Haspin19 and the overexpression of Repo-Man.17 Collectively these results demonstrate that PDP3 activates PP1 in living cells.
In conclusion, we have developed a cell-permeable peptide (PDP3) that competes with endogenous RVxF-containing PIPs for binding to PP1 in living cells, but does not bind the closely related phosphatase PP2A. Our design strategy demonstrates that a simple modification of peptides with an unnatural amino acid can impart remarkable in-cell stability to peptides. In addition, we show that carefully designed cell-penetrating peptides do not show nonspecific cytotoxicity as a result of the polybasic stretch. Our results demonstrate that, together with cell-penetrating properties, the balance between in vitro activity (PDP3 has higher EC50 than the precursor peptides) and in-cell stability is crucial for peptidic probes. We observed that by blocking PIP–PP1 interactions and promoting auto-dephosphorylation, PDP3 generates active PP1 that efficiently dephosphorylates a subset of PP1 substrates. In accordance with biochemical and structural studies, our data reveal that a major function of PIPs is to restrain PP1 from dephosphorylating proteins in an uncontrolled manner.7, 20 Our study also shows that it is possible to selectively activate PP1 in living cells, opening up new routes to decipher PP1 signaling.3 The fact that addition of PDP3 leads to the same outcome on H3T3 phosphorylation as treatment with an inhibitor of the H3T3 kinase Haspin21 suggests that PDP3 (derivatives) or equivalent small molecules may have therapeutic potential as antagonists of pathologically increased kinase signaling. In addition, these compounds potentially can be used as sensitizers of kinase inhibitors that are used clinically. Furthermore, the crystal structure of PP1:PDP2 can serve as a template for the design of further potent peptide/peptidomimetic analogues to disrupt PP1–PIP interactions.
Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.